

GlaxoSmithKline increases investments in Egypt to EGP 1 bln

GlaxoSmithKline Consumer Healthcare has said that it will invest EGP 100 million in 2019, increasing its investments in Egypt to a total of EGP 1 billion. The British drugmaker has inaugurated an EGP 20 million Voltaren production line at its plant in Giza.